Tarik Silk, Ursula A Matulonis, Panagiotis A Konstantinopoulos
Endometrial cancers classified as having no specific molecular profile (NSMP) represent the most prevalent molecular subtype of the disease. In this review, we summarize the immunogenomic landscape and phenotypic features of NSMP endometrial cancer and discuss current and emerging therapeutic strategies, including endocrine therapies, targeted agents, immunotherapies, and antibody-drug conjugates. We further highlight the need for future clinical trials to incorporate molecular stratification and prioritize the development of predictive biomarkers and rational combination approaches to improve outcomes for patients with NSMP endometrial cancer.